Publicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (12)

2023

  1. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 4, pp. 711-722

2022

  1. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 9, pp. 2367-2374.e3

  2. The impact of the initial COVID-19 outbreak on young adults’ mental health: a longitudinal study of risk and resilience factors

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Author Correction: c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis (Nature Metabolism, (2020), 2, 11, (1350-1367), 10.1038/s42255-020-00306-2)

    Nature Metabolism

  2. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

2020

  1. c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis

    Nature Metabolism, Vol. 2, Núm. 11, pp. 1350-1367

2018

  1. Encompassing new use cases - Level 3.0 of the HUPO-PSI format for molecular interactions

    BMC Bioinformatics, Vol. 19, Núm. 1

2007

  1. The minimum information required for reporting a molecular interaction experiment (MIMIx)

    Nature Biotechnology, Vol. 25, Núm. 8, pp. 894-898

2005

  1. The participation of health professionals in a smoking-cessation programme positively influences the smoking cessation advice given to patients

    International Journal of Clinical Practice, Vol. 59, Núm. 4, pp. 447-452

2001

  1. Effect of amine structure and reaction additives on enantioselective deprotonations mediated by homochiral magnesium amide bases

    Tetrahedron Letters, Vol. 42, Núm. 40, pp. 7111-7114

1992

  1. Lipidic peptides. VIII. Cellular uptake studies of lipidic amino acid, its oligomers and highly lipophilic drug conjugates

    International Journal of Pharmaceutics, Vol. 79, Núm. 1-3, pp. 39-45

  2. Lipidic peptides. XII. Cellular uptake studies of a lipidic amino acid, its oligomers and highly lipophilic drug conjugates on Ehrlich ascites tumour cells

    International Journal of Pharmaceutics, Vol. 83, Núm. 1-3, pp. 131-138